ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.67
-0.29 (-3.24%)
At close: Mar 6, 2026, 4:00 PM EST
8.58
-0.09 (-1.04%)
After-hours: Mar 6, 2026, 4:34 PM EST
ImmunityBio Employees
As of December 31, 2025, ImmunityBio had 691 total employees, including 684 full-time and 7 part-time employees. The number of employees increased by 11 or 1.62% compared to the previous year.
Employees
691
Change (1Y)
11
Growth (1Y)
1.62%
Revenue / Employee
$163,948
Profits / Employee
-$508,535
Market Cap
8.91B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Exelixis | 1,077 |
| Axsome Therapeutics | 925 |
| Madrigal Pharmaceuticals | 915 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
IBRX News
- 2 days ago - ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 - Business Wire
- 8 days ago - ImmunityBio Investors Rally Behind Cancer Trial Milestone - Benzinga
- 8 days ago - ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
- 9 days ago - ImmunityBio Supersedes Expectations With Fivefold Revenue Increase - Benzinga
- 9 days ago - ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate - Benzinga
- 11 days ago - ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit - Business Wire
- 11 days ago - ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth - Benzinga